SRR3147732
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.330
- PROTEIN_SECRETION+0.310
- APICAL_SURFACE+0.300
- HEME_METABOLISM+0.190
- BILE_ACID_METABOLISM+0.160
- ESTROGEN_RESPONSE_EARLY+0.150
- COAGULATION+0.130
- MYOGENESIS+0.110
- NOTCH_SIGNALING+0.070
- XENOBIOTIC_METABOLISM+0.060
Top 10 suppressed
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.490
- MYC_TARGETS_V1-0.420
- TNFA_SIGNALING_VIA_NFKB-0.400
- MTORC1_SIGNALING-0.350
- ALLOGRAFT_REJECTION-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
- INTERFERON_ALPHA_RESPONSE-0.310
- IL6_JAK_STAT3_SIGNALING-0.300
- MYC_TARGETS_V2-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR27320668 | — | — | 0.841 |
| 2 | SRR8613701 | — | A | 0.839 |
| 3 | C3L-02958 | — | cohortA1 | 0.820 |
| 4 | SRR1313106 | — | B | 0.818 |
| 5 | C3N-02973 | — | cohortA1 | 0.805 |
| 6 | SRR975563 | — | — | 0.798 |
| 7 | SRR8613714 | — | A | 0.795 |
| 8 | C3L-03679 | — | cohortA1 | 0.791 |
| 9 | BS_CGB2WS2A | pilocytic astrocytoma | — | 0.789 |
| 10 | MDT-AP-0810 | Med | Medulloblastoma | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |